Oliceridine on Postoperative Nausea and Vomiting in Gynecological Laparoscopic Surgery

Launched by YANYING XIAO · Jun 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medicine called Oliceridine to see if it can help reduce nausea and vomiting after gynecological laparoscopic surgery, which is a minimally invasive surgery on the female reproductive organs. The trial will compare Oliceridine to another commonly used pain medicine called sufentanil to find out which one causes less nausea and vomiting after surgery. The study will also check how safe Oliceridine is for patients during and after the surgery.

Women between the ages of 18 and 65 who are having planned gynecological laparoscopic surgery and meet certain health criteria may be eligible to join. Participants will receive either Oliceridine or sufentanil for pain relief during and after their operation. Doctors will monitor their vital signs during surgery and watch for any nausea or vomiting afterward for at least 48 hours. People with serious health problems, allergies to certain medicines, or who are pregnant or breastfeeding will not be able to take part. The study aims to help improve comfort and safety for women having this type of surgery.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • 1. Elective gynecological laparoscopic surgery;
• • 2. Age 18-65 years;
• • 3. ASA physical status I-III;
• • 4. Body mass index (BMI) 18-30 kg/m².
• Exclusion criteria:
• • 1. Severe dysfunction of major organs such as the heart, lungs, or brain;
• • 2. History of allergy to opioid drugs, propofol, soybeans, or eggs;
• • 3. Recent use of sedatives, analgesics, or monoamine oxidase inhibitors;
• • 4. History of alcohol abuse;
• • 5. Obstructive sleep apnea syndrome;
• • 6. Difficult airway;
• • 7. Psychiatric or neurological disorders; communication disorders;
• • 8. Women who are lactating or pregnant.
• Withdrawal criteria:
• • 1. Subject requests withdrawal or withdraws voluntarily;
• • 2. Change in surgical method requiring combined gastrointestinal surgery;
• • 3. Occurrence of allergy to the investigational drug or life-threatening complications;
• • 4. Reoperation within 48 hours postoperatively due to bleeding or other factors.